What is HC Wainwright’s Forecast for LXEO FY2025 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Monday, November 17th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.00) for the year, up from their previous estimate of ($2.21). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q4 2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.34) EPS.

Several other equities research analysts also recently issued reports on LXEO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Leerink Partners raised their target price on Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Oppenheimer began coverage on Lexeo Therapeutics in a research report on Thursday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. Guggenheim started coverage on Lexeo Therapeutics in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $18.57.

Lexeo Therapeutics Trading Down 3.2%

NASDAQ LXEO opened at $9.18 on Wednesday. The stock has a market cap of $670.05 million, a P/E ratio of -3.40 and a beta of 1.75. The company’s fifty day simple moving average is $7.81 and its 200-day simple moving average is $5.39. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $10.38.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC raised its stake in Lexeo Therapeutics by 10.6% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock worth $110,000 after acquiring an additional 1,595 shares during the period. Bank of America Corp DE boosted its stake in Lexeo Therapeutics by 6.1% in the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after acquiring an additional 1,626 shares during the period. Intech Investment Management LLC grew its holdings in shares of Lexeo Therapeutics by 20.7% during the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after purchasing an additional 2,342 shares during the last quarter. AXQ Capital LP raised its position in shares of Lexeo Therapeutics by 19.6% during the 3rd quarter. AXQ Capital LP now owns 14,921 shares of the company’s stock worth $99,000 after purchasing an additional 2,446 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Lexeo Therapeutics by 42.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the company’s stock worth $63,000 after purchasing an additional 2,799 shares during the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Lexeo Therapeutics

In related news, insider Tai Sandi See sold 3,888 shares of Lexeo Therapeutics stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $34,758.72. Following the completion of the transaction, the insider directly owned 65,862 shares in the company, valued at approximately $588,806.28. This trade represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Richard Nolan Townsend sold 13,133 shares of the business’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $117,409.02. Following the completion of the sale, the chief executive officer directly owned 242,118 shares of the company’s stock, valued at approximately $2,164,534.92. This represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 22,518 shares of company stock valued at $201,311. Insiders own 5.30% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.